Anti-Steroid 5-alpha-reductase 1 (SRD5A1) Antibody
This rabbit IgG polyclonal antibody was generated against a multiple antigen peptide and is specific for human steroid 5-alpha-reductase 1 (SRD5A1).
Highlights:
- Reacts with human SRD5A1 (epitope: RNRQTNSVYGRHALPSHRLR)
- Suitable for for Western Blot and Immunohistochemistry applications
Steroid 5-alpha-reductase 1 (SRD5A1) is an enzyme that converts testosterone to the more potent dihydrotestosterone in the prostate. Levels of SRD5A1 are increased in prostate cancer compared to benign tissue. It also plays a role in sexual differentiation and androgen physiology.
From the laboratory of Catherine K. L. Too, PhD, Dalhousie University.
This rabbit IgG polyclonal antibody was generated against a multiple antigen peptide and is specific for human steroid 5-alpha-reductase 1 (SRD5A1).
Highlights:
- Reacts with human SRD5A1 (epitope: RNRQTNSVYGRHALPSHRLR)
- Suitable for for Western Blot and Immunohistochemistry applications
Steroid 5-alpha-reductase 1 (SRD5A1) is an enzyme that converts testosterone to the more potent dihydrotestosterone in the prostate. Levels of SRD5A1 are increased in prostate cancer compared to benign tissue. It also plays a role in sexual differentiation and androgen physiology.
From the laboratory of Catherine K. L. Too, PhD, Dalhousie University.
Specifications
| Product Type: | Antibody |
| Alternative Name(s): | 3-oxo-5-alpha-steroid 4-dehydrogenase 1 ,SR type 1, Steroid 5-alpha-reductase 1, SRD5A1 |
| Antigen: | Steroid 5-alpha-reductase 1 (5αR1) |
| Accession ID: | P18405, NM_001047 |
| Isotype: | IgG |
| Clonality: | Polyclonal |
| Reactivity: | Human |
| Immunogen: | Multiple antigen peptide |
| Species Immunized: | Rabbit |
| Epitope: | RNRQTNSVYGRHALPSHRLR |
| Purification Method: | Affinity-purified |
| Method Used to Determine Concentration: | BCA assay |
| Buffer: | Anti-microbial borate buffered saline with 1% BSA |
| Tested Applications: | WB (1 - 2 µg/ml), IHC (3 µg/ml) |
| Storage: | -80 |
| Shipped: | Cold Packs (Domestic, Overnight); Dry Ice (International) |
Provider
From the laboratory of Catherine K. L. Too, PhD, Dalhousie University.
References
- Thomas LN, Douglas RC, Lazier CB, Gupta R, Norman RW, Murphy PR, Rittmaster RS and Too CKL. Levels of 5α-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer. J Urol. 2008;179(1):147-51.
- Lunacek A, Schwentner C, Oswald J, Fritsch H, Sergi C, Thomas LN, Rittmaster RS, Klocker H, Neuwirt H, Bartsch G and Radman C. Fetal distribution of 5α-reductase 1 and 5α-reductase 2, and their imput on human prostate development. J Urol. 2007;178(2):716-721.
- Thomas LN, Lazier CB, Gupta R, Norman RW, Troyer DA, OBrien SP and Rittmaster RS. Differential alterations in 5α-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate. 2005;63(3):231-239.
- Titus MA, Gregory CW, Ford III OH, Schell MJ, Maygarden SJ and Mohler JL. Steroid 5α-reductase isoenzymes I and II in recurrent prostate cancer. Clin Cancer Res. 2005;11(12):4365-4371.
- Thomas LN, Douglas RC, Vessey JP, Gupta R, Fontaine D, Norman RW, Thompson IM, Troyer DA, Rittmaster RS and Lazier CB. 5α-Reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. J Urol.2003:170(5):2019-2025.
If you publish research with this product, please let us know so we can cite your paper.
